Treatment of Children and Adolescents with Epilepsy with Atomoxetine.
Psychiatry Investig
; 17(5): 412-416, 2020 May.
Article
in En
| MEDLINE
| ID: mdl-32295327
ABSTRACT
OBJECTIVE:
The objective of this study was to assess the effectiveness and safety of atomoxetine in Korean children and adolescents with epilepsy.METHODS:
We retrospectively reviewed the electronic medical records of 105 children and adolescents with epilepsy treated with atomoxetine. Effectiveness was measured with the Clinical Global Impressions-Severity (CGI-S) and/or Clinical Global Impressions-Improvement (CGI-I) scales at baseline, and after 4 and 12 weeks. We defined response to atomoxetine as a CGI-I score less than three at week 12. Safety was evaluated at each visit, based on clinical assessment by a child and adolescent psychiatrist and reports from participants or their caregivers.RESULTS:
In total participants (n=105), 33 (31.4%) showed a response to treatment a significant decrease in CGI-S scale score was observed over 12 weeks of atomoxetine treatment. The most common adverse event (AE) was decreased appetite (n=16, 15.2%), and life-threatening AEs were not observed. Seizure aggravation due to atomoxetine was observed in 7.6% (n=8) of total participants, and one of them discontinued atomoxetine.CONCLUSION:
Our results provide preliminary evidence of the effectiveness and safety of atomoxetine in children and adolescents with epilepsy.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Psychiatry Investig
Year:
2020
Document type:
Article